VAM
LAB icon

Visium Asset Management’s Standard BioTools LAB Stock Holding History

Visium Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-95,200
Closed -$2.8M – 1134
2014
Q2 		$2.8M Sell
95,200
-267,790
-74% -$8.58M 0.04% 335
2014
Q1 		$16M Buy
362,990
+218,731
+152% +$9.62M 0.26% 79
2013
Q4 		$5.53M Sell
144,259
-224,698
-61% -$6.62M 0.11% 187
2013
Q3 		$8.1M Buy
368,957
+68,057
+23% +$1.34M 0.18% 91
2013
Q2 		$5.25M Buy
+300,900
New +$5.28M 0.12% 122

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Visium Asset Management's LAB Position: Q3 2014 in Review

Visium Asset Management sold out of Standard BioTools (LAB) in Q3 2014, closing a stake of 95,200 shares — an estimated $2.8M sold.

Visium Asset Management first reported a position in LAB in Q2 2013 and held it in 5 quarters. The position peaked at $16M in Q1 2014. 99 funds tracked by Wall St. Rank hold LAB as of Q3 2014.

  • Visium Asset Management reported no remaining Standard BioTools position as of Q3 2014 after selling out during the quarter.
  • Visium Asset Management sold 95,200 Standard BioTools shares in Q3 2014, an estimated $2.8M.
  • Visium Asset Management first reported a position in Standard BioTools in Q2 2013 and held it in 5 quarters.
  • Visium Asset Management's Standard BioTools position peaked at $16M in Q1 2014.
  • 99 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2014.

Based on Visium Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.